RxDoctor Payments Data

Kathleen Stidham

Family · Pasco, WANPI 1487814331

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,086 of the $5,751 with a category attached, or 88.4%. It is spread thinly across 24 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,751in general payments, 2019–2025

Across 309 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1000
  • Novartis$585
  • UCB, Inc.$368
  • E.r. Squibb & Sons, L.L.C.$357
  • Sun Pharmaceutical Industries Inc.$328
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$5,08688%
  • Education$66512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,751 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$138,936
Medicare patients
557
Services billed
1,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$60,456
Dupixent PenDupilumab13$46,273
Clobetasol Propionate49$2,136
Doxycycline Hyclate42$907
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet13$420
Imiquimod16$350
Triamcinolone Acetonide18$88
Ketoconazole19$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$258$60,45612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.

Other family in Pasco

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →